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Running title: PTLD following KTx in Japan 
 
Abstract  
Post-transplant lymphoproliferative disorder is a serious complication of solid organ transplantation; 
however, few large studies have been performed in Asian institutions. We review our single-center 
experience with post-transplant lymphoproliferative disorder patients in Japan. We retrospectively 
evaluated patients with post-transplant lymphoproliferative disorder following kidney transplantation 
between January 1985 and December 2013. The patients were divided into early-onset post-transplant 
lymphoproliferative disorder (< 1 year) and late-onset post-transplant lymphoproliferative disorder (≥ 
1 year) groups. Thirteen patients had the disorder, an incidence rate of 0.75% (13/1730). Early-onset 
post-transplant lymphoproliferative disorder (n=3) had not occurred for the last 2 decades. In the late-
onset group (n = 10), the median time of onset was 108.7 months. The Kaplan-Meier 10-year overall 
survival rates were 76.9% and 95.4% in patients with and without the disorder, respectively 
(p=0.0001). Post-transplant lymphoproliferative disorder significantly affected transplant recipients’ 
mortality. Late-onset occurred even > 10 years after transplantation; therefore, long-term monitoring 
of patients is needed.  
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Introduction 
 Post-transplant lymphoproliferative disorder (PTLD) occurs in approximately 0.4% to 2.0% of 
kidney transplant recipients, and potentially influences their mortality (1-4). Previously reported 
survival rates have been poor, with mortality rates exceeding 50% in most studies (5-7). Although 
several recent studies have reported that administration of rituximab (RTX) and/or chemotherapy can 
effectively prevent disease progression (8-10), PTLD has remained one of the most morbid post-
transplant complications. Some cases of PTLD occur within the early period after transplantation 
(early-onset PTLD), whereas others develop more than 1 year after transplantation (late-onset PTLD) 
(4, 11-13). Several differences between early- and late-onset PTLD, including risk factors, prognostic 
outcomes, and clinical and histopathological characteristics, have been previously described (4, 11, 
12, 14).  
In the present study, we retrospectively reviewed patients who developed PTLD after kidney 
transplantation in our department over approximately 30 years. Clinical and immunohistological 
characteristics were analyzed, and patient and graft outcomes were also evaluated with reference to 
recent studies.  
 
4 
 
Patients and methods 
After institutional review board approval (ID: 3440), the Tokyo Women’s Medical University 
medical record archive between January 1985 and December 2013 were retrospectively reviewed. 
This study was performed in accordance with the principles outlines in the Declaration of Helsinki. 
Written informed consent was obtained from all patients. Clinical and laboratory data were extracted 
from an electronic database and patient medical records. PTLD was pathologically diagnosed by at 
least two experienced pathologists after performing needle or open tissue biopsy according to the 2008 
world health classification system, and divided into the following groups: early lesions, polymorphic 
PTLD, monomorphic PTLD, or classical Hodgkin lymphoma-type PTLD. Clinical stage was 
determined according to the Ann Arbor Staging System. Epstein-Barr virus (EBV) association was 
analyzed according to the protocol at our center using LMP-1 and/or EBNA-2 immunohistochemistry 
or EBER in situ hybridization. EBV viral load was determined using deoxyribonucleic acid (DNA)-
polymerase chain reaction, and sample positivity was defined as more than 2.0×10 copies. Late-onset 
PTLD was defined as development more than 1 year after transplantation, whereas early-onset PTLD 
developed within 1 year. 
 
Immunosuppressive protocol 
In general, before 1990, cyclosporine (CYA), methylprednisolone (MP), and azathioprine (AZ) or 
mizoribine (MZ) were used in ABO-compatible and minor-mismatch transplants. Additionally, 
antilymphocyte globulin (ALG) and deoxyspergualine (DSG) were administered for ABO-
incompatible transplantation. Starting in 1990, tacrolimus (FK) was used as an alternative to CYA. 
Since 1998, mycophenolate mofetil (MMF) has been used as an alternative to AZ or MZ. Since 2000, 
immunosuppressive regimens consisting of FK, MMF and MP have been generally used. Since 2004, 
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basiliximub (BSX) has been administered at the time of transplantation in all cases. Moreover, single-
dose RTX (200mg) has been administered in ABO-minor-mismatch, -incompatible, or hyper-
sensitized transplantation cases since 2005. Splenectomy was performed simultaneously to 
transplantation in ABO-incompatible recipients until 2005.  
 
PTLD evaluation  
As the immunosuppressive background was different between the pre-2000 and post-2000 eras, all 
recipients with and without PTLD were divided into four groups (one for each era, one with PTLD, 
and one without PTLD), and these groups were compared to each other. Moreover, PTLD patients 
were divided into early- and late-onset PTLD subgroups, which were individually compared and 
evaluated for their clinical and histopathological characteristics, and outcome of PTLD.   
 
Statistical analysis  
 Recipients’ demographic characteristics were compared between the two eras (pre-2000 and post-
2000) using the Mann-Whitney U test or χ2-test. Overall survival and graft survival were estimated 
using the Kaplan-Meier method and compared using the log-rank test. A difference was considered 
significant at p <0.05. All analyses were performed using the JMP® 11 software package (SAS Institute 
Inc., Cary, NC, USA).  
 
Results  
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Demographic characteristics of all recipients with and without PTLD between the pre-2000 and post-
2000 eras 
 All recipients were divided into four subgroups as follows: patients without PTLD before 2000, those 
with PTLD before 2000, patients without PTLD since 2000, and those with PTLD since 2000. 
According to aforementioned subgroups, 540, 7, 1177, and 6 patients were categorized, respectively. 
Mean age at the time of transplantation was 36.3 and 44.3 years in the pre-2000 and post-2000 eras, 
respectively; the number of elder recipients significantly increased in the post-2000 compared to that 
in the pre-2000 era (p<0.0001). The rate of men was not significantly different between the pre-2000 
and post-2000 eras (65.8% vs. 62.4%, respectively; p=0.168). The rate of living donor and ABO-
incompatible transplantation significantly increased in the post-2000 compared to that in the pre-2000 
era (p=0.0373 and p<0.0001, respectively). Notably, the uniformity of the immunosuppressive 
regimen, which consisted of FK, MMF, and MP, was confirmed in the post-2000 era; FK, MMF, and 
MP were used in 97.4%, 92.3%, and 100.0% of patients compared with 25.6%, 10.1%, and 100.0% 
of patients in the pre-2000 era (all, p<0.0001). The rate of EBV seropositivity seemed to be 
significantly different between the two eras (p<0.0001); however, this result had a lower reliability 
due to the high rate of unknown data, especially in the pre-2000 era (74.0%). The incident rate of 
overall PTLD-onset was lower in the post-2000 era than in the pre-2000 era (0.51 % vs. 1.28 %; 
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statistical analysis was not performed because of the small number of patients), and early-onset PTLD 
has not occurred since 2000.  
 
Individual clinical and histopathological characteristics of PTLD between the early- and late-onset 
PTLD groups 
Overall 13 patients had PTLD, accounting for an incidence rate of 0.75% (13/1730). The median age 
in the early- and late-onset group was 32.7 years (range 26-45) and 53.9 years (range 34-68), 
respectively. Only 1 PTLD patient was a woman. The reasons for end-stage kidney disease were 
chronic glomerulonephritis and IgA nephropathy in 7 and 3 patients, respectively, and interstitial 
nephritis, polycystic kidney disease, and reflux nephropathy each in 1 patient. The median duration of 
dialysis therapy prior to transplantation was 62.3 months (range 4-180). Five patients underwent 
deceased donor transplantation, and 8 patients underwent living donor transplantation. Only 1 patient, 
no. 10, underwent a second kidney transplantation. No patients underwent other organ transplantations. 
ABO was compatible, minor-mismatch, and incompatible in 8, 3, and 2 patients, respectively. Twelve 
patients received an initial immunosuppressive regimen consisting of calcineurin inhibitor (CYA, FK), 
antimetabolite (AZ, MZ, MMF), and corticosteroid (MP). Only 1 patient, no. 12, received an mTOR-
inhibitor (everolimus) as part of a clinical trial. Splenectomy was performed in patient nos. 1 and 2. 
BSX was inducted in all 4 patients since 2004. EBV serostatus was positive in 8 patients, and negative 
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in 3 patients (data from 2 patients were unavailable). All patients in the early-onset group received 
anti-rejection treatments prior to PTLD: all received steroid pulse therapy and muromonab-CD3, and 
patients no. 1 and 2 additionally were administered DSG. Meanwhile, in the late-onset group, only 
patient no. 11 received treatments including steroid pulse therapy and DSG before PTLD. The median 
time from transplantation to PTLD onset was 3.67 months (range 1-8) and 108.7 months (range 14-
250) in the early- and late-onset groups, respectively. All patients in the early-onset group were 
diagnosed as stage IV according to Ann Arbor staging, whereas 7 patients in the late-onset group were 
diagnosed as stage III or IV. Histopathologically, diffuse large B-cell lymphoma (DLBCL) was 
diagnosed in 6 patients. Non B-cell lymphoma was diagnosed in 2 patients: Hodgkin’s lymphoma with 
mixed cellularity in patient no. 7 and monomorphic T-cell lymphoma in patient no. 10. EBV-
associated PTLD occurred in 1 patient in the early-onset group (data in 2 patients unknown), and 6 
patients in the late-onset group (data in 1 patient unknown). In the late-onset group, the viral load of 
EBV in the serum was elevated in 4 patients. The viral load in the cerebrospinal fluid (CSF) was also 
elevated in patient nos. 4 and 10, who had central nervous system (CNS)-PTLD despite EBV 
negativity in the serum. At PTLD onset, all patients in the late-onset group received an 
immunosuppressive regimen consisting of FK, MMF and MP because CYA was converted to FK, and 
AZ or MZ was converted MMF in 2000 in our department (Table 2).  
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Individual treatments, and patient and graft outcomes of PTLD between the early- and late-onset 
PTLD groups 
Immunosuppression reduction (IR) was performed in all patients; antimetabolic drugs were 
withdrawn in all patients, and calcineurin inhibitors were withdrawn in all early-onset patients and in 
4 late-onset patients. Surgery was performed in 3 patients: patient no. 3 underwent graftectomy for 
graft PTLD, patient no. 11 underwent surgery for an invasive tumor in the small intestine, and patient 
no. 13 underwent intracranial decompression for cerebral hernia due to invasive CNS tumor. Radiation 
therapy and chemotherapy were performed in 4 and 5 patients, respectively, and rituximab-associated 
chemotherapy was administered in 3 of 5 patients. The median time of follow-up was 61.7 months 
(range 1-183) and 46.1 months (range 2-124) in the early- and late-onset group, respectively. Two of 
3 patients in the early-onset group died of PTLD 1 month after onset. In the late-onset group, 8 patients 
were alive; 7 and 1 patients were diagnosed as complete response and stable disease, respectively; and 
2 patients died of PTLD and Pneumocystis jiroveci pneumonia due to bone-marrow suppression 
associated with chemotherapy, respectively. Two and 4 patients had graft loss in the early- and late-
onset group, respectively. Among graft-loss patients, except for patient no. 5, graft function was 
rapidly eliminated within several months (Table 3). 
 
Overall survival and graft survival in patients with PTLD, late-onset PTLD and without PTLD 
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Kaplan-Meier curves predicted worse overall survival rates for patients with overall PTLD and late-
onset PTLD compared to those without PTLD (Fig. 1). While overall survival rates were significantly 
worse in patients with overall PTLD than those without PTLD (76.9% vs. 97.4% at 5 years, 76.9% vs. 
95.4% at 10 years, 65.93% vs. 91.0% at 20 years after transplantation, p=0.0001), there was no 
significant difference in overall survival between patients with late-onset PTLD and patients without 
PTLD (p=0.078). Neither PTLD nor late-onset PTLD were significantly associated with graft survival, 
compared to patients without PTLD (p=0.1612, p=0.7179, respectively) (Fig. 2). 
 
Overall survival and graft survival in patients with late-onset PTLD from onset 
The 5- and 7-year overall survival rates after late-onset PTLD were 90.0% and 60.0%, respectively 
(Fig. 3). The 1- and 5-year graft survival rates after late-onset PTLD were 80.0% and 40.0%, 
respectively (Fig. 4). 
 
Discussion 
In recent years, large-scale studies for PTLD have been performed and revealed several differences 
between early- and late-onset PTLD, not only in risk and prognostic factors but also patient and graft 
outcome. However, the number of such reports has been limited in Asian institutions: to the best of 
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our knowledge, only 2 retrospective studies of single-center experience in China (15) and Japan (16), 
have been reported.  
A large retrospective study reported that the risk factors of early-onset PTLD were considered to be 
younger age and EBV or cytomegalovirus seronegativity, whereas older age is associated with late-
onset PTLD (4). In the present study, patients in the late-onset group were older than those in the early-
onset group, consistent with this previous investigation. Furthermore, all patients in the early-onset 
group were administered antirejection drugs such as muromonab-CD3, which are regarded as a risk 
factor of early-onset PTLD (7, 14). Several studies reported that the pathogenesis of PTLD differs 
between early- and late-onset PTLD, with most early-onset PTLD cases triggered by primary EBV 
infection via donor lymphocytes, frequently located within the allograft, resulting from proliferating 
latently infected B-cells in the absence of a normal cytotoxic T-cell response under the 
immunosuppression. Indeed, more cases with B-cell lymphoma associated with EBV (14), or 
presentation in the allograft (11, 17) have been described to develop early-onset PTLD. Meanwhile, 
late-onset PTLD sometimes develops in an extra-nodal or CNS lesion (1), and likely presented a 
reduced rate of B-cell lymphoma associated with EBV and slightly more cases originating from T-
cells (4). In the patients with late-onset PTLD in the present study, the rates of both B-cell lymphoma 
and EBV-association were apparently more frequent than have been reported previously. Additionally, 
extra-nodal presentation and CNS involvement were observed in 7 and 2 patients, respectively, while 
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no graft-PTLD developed. In patient nos. 4 and 13, we did not detect elevated EBV load in the serum 
but rather in the CSF, indicating EBV-associated CNS-PTLD. In patients with CNS lesions, detection 
of EBV load in the serum can result in negative results (18); therefore, examination of CSF samples 
is recommended (14). Furthermore, in patient no. 10, who had primary cutaneous PTLD, elevated 
EBV load was not apparent in the serum, but histopathological findings from tissue indicated a 
diagnosis of EBV-associated monomorphic T-cell lymphoma. These results suggest that the EBV load 
in the serum should not be the only method of EBV diagnosis, especially in cases involving localized 
lesions such as CNS or cutaneous PTLD. 
Our analysis demonstrated that PTLD significantly increased the morbidity of kidney transplant 
recipients compared with patients without PTLD (p<0.0001). Early-onset PTLD patients in particular 
had worse progression. Patients with late-onset PTLD also demonstrated a trend toward worse 
outcome, although the difference was not statistically significant (p=0.078). High staging, CNS, and 
bone marrow involvement are regarded as independent risk factors for poor progression (10, 12, 14). 
In the present study, the patients in the early-onset group were initially diagnosed at advanced stage. 
Patient nos. 1 and 2, had CNS lesion and bone marrow involvement, respectively, and died 
immediately. Patient no. 3 had graft involvement with multiple surrounding lymph node metastasis, 
and graftectomy and lymph node dissection were performed. Postoperatively, the tumors did not recur 
or metastasize for 183 months. Graft-PTLD, which commonly develops in the early post-transplant 
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period, has been reported to show better outcomes (6, 12). Caillard et al. explained that graft-PTLD 
has a tendency to be detected earlier than other forms of PTLD due to intense monitoring of 
transplanted organs during the early post-transplant period and easier accessibility for surgical 
resection (12). Conversely, the patients in the late-onset group tended to demonstrate slower 
progression in the present study. We speculate that this difference is due to their better response to IR 
as an initial treatment. Nonetheless, patient no. 9 died 65 months after PTLD diagnosis despite 
chemotherapy including sequential treatment with RTX followed by cyclophosphamide, doxorubicin, 
vincristine and prednisolone (CHOP). Multiple and/or extranodal lesions, including the orbit, lung, 
testis and abdominal lymph nodes; high staging; and absence of EBV association were identified as 
risk factors according to previous reports (12, 14). Patient no. 10 died of Pneumocystis jiroveci 
pneumonia during chemotherapy only 2 months after PTLD diagnosis, which was caused by 
myelosuppression as an adverse effect of chemotherapy. 
Sequential treatment with RTX followed by CHOP chemotherapy is regarded as an effective and 
safe treatment for PTLD patients, especially for B-cell PTLD (8). Other studies also demonstrated the 
effectiveness of RTX therapy; Michonneau et al. (9) reported that 5-year overall survival and disease-
free survival were 69% and 80%, respectively in patients who received RTX with or without 
chemotherapy treatment, whereas Evens et al. (10) reported 3-year progression-free survival and 
overall survival were 70% and 73 %, respectively. We used RTX-associated chemotherapy in 3 
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patients. No patients in the early-onset group were administered RTX because the chemotherapy 
regimen did not include RTX at that time. Patients no. 4 and 10 were administered chemotherapy 
without RTX for severe kidney dysfunction. Patient no. 13 was already in a state of brain-death after 
the surgery; therefore overly stressful chemotherapy was not performed. Meanwhile, graft survival 
following late-onset PTLD appeared to be poorer than that in previous studies (19). IR is commonly 
performed as an initial treatment for PTLD because impairment of the immunological system is a 
major trigger of PTLD, although the rejection caused by reduction of immunosuppressive conditions 
remains an unresolved problem. In fact, some patients who received IR suffered from graft loss in the 
present study. Rabot et al. reported that calcineurin inhibitor withdrawal could adversely influence 
graft and patient survival (19). Meanwhile, RTX and CHOP chemotherapy can be effective for 
maintaining graft function (20). 
In the present study, several interesting trends were observed. First, the rate of early-onset PTLD is 
apparently lower than that of late-onset PTLD, and notably, it had not occurred for the last 2 decades. 
Second, late-onset PTLD was more likely to occur much later in the post-transplant period; the median 
time to onset from transplantation was over 100 months, and the longest time was up to 250 months. 
There are several possible reasons for this late onset. Regarding the first reason, RTX, which is used 
in cases of ABO minor-mismatch, incompatibility, or hyper-sensitized transplantation, may be 
effective for preventing early-onset PTLD. Our previous study demonstrated that single-dose RTX 
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has the effect of B-cell depletion for approximately 2 years (21). The rate of overall PTLD-onset in 
the recent era was also lower than that in the previous era (0.51 % vs 1.28 %) despite a higher rate of 
negative EBV serostatus (5.95 % vs 2.59 %), as shown in Table 1. This may be associated with RTX 
administration. However, this hypothesis must be tested; the effectiveness of RTX has been 
established as a treatment of PTLD but not as PTLD prophylaxis. Therefore, more detailed research 
is needed regarding whether RTX can be effective as a prophylaxis therapy for early-onset PTLD. 
Regarding the second reason, late-onset PTLD may have been caused by the fact that the population 
in the post-2000 era was significantly older than that in the pre-2000 era; the age was regarded as an 
independent factor according to the aforementioned study (4). Third, in the recent decade between 
2001 and 2010, PTLD-onset seems to have occurred rather earlier than in the previous era, and was 
diagnosed at advanced stage (more than stage 4 in all cases). This outcome may be caused by using 
MMF, which is a powerful immunosuppressive agent. Several reports have previously indicated that 
MMF administration may affect the high incidence of PTLD-onset (22, 23). Furthermore, compared 
to patients in the post-2000 era, PTLD in patient nos. 7 and 8 occurred relatively later in the transplant 
period despite receiving the same immunosuppressive drugs such as FK, MMF, and MP. This 
discrepancy may have been caused by BSX administration as an initial immunosuppressive agent, 
which has been used since the recent decade. MMF and a currently powerful immunosuppressive 
regimen, including FK, MMF, MP and BSX, may cause outbreak in earlier after transplantation or 
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during the more aggressive progression of PTLD.  
Moreover, an epidemiological difference in EBV prevalence has been recognized between Asia and 
Western countries; Asian children and young adults infected with EBV at an earlier age, and more 
than 95% of adults are seropositive. By contrast, the rate of seropositive adolescents and young adults 
ranges from 50% to 70% in the West (15), which therefore may increase the rate of early-onset PTLD. 
Chan et al. also reported PTLD characteristics similar to our results (15). In their institution, EBV-
positive PTLD represented the majority of the late-onset group, and the time from transplantation to 
onset was substantially longer than reported in Western countries. They speculated that the reason for 
this result was the higher rate of EBV positivity in Asian countries, reflecting a much longer time 
required for EBV lymphomagenesis as a result of reactivation of latent EBV infection (15). In our 
study, 7/10 late-onset PTLD cases were associated with EBV, indicating similar tendencies in these 2 
Asian studies. It may be necessary to establish specific guidelines for PTLD in Asian populations, 
including risk factors, prognostic indicators, diagnostic criteria and outcome. 
 
Conclusion 
We reviewed PTLD patients with regard to clinical and histopathological characteristics, as well as 
patient and graft outcomes. The present study demonstrated that PTLD significantly impacted kidney 
transplant recipients’ mortality, and also observed several interesting characteristics. First, the rate of 
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early-onset PTLD is apparently lower than that of late-onset PTLD, and notably has not occurred in 
the modern era. Second, late-onset PTLD was more likely to occur much later in the post-transplant 
period. Long-term and regular observation is needed to detect late-onset PTLD, and larger 
investigations re-evaluating PTLD characteristics in an Asian multi-center study should be performed, 
if possible. 
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Figure legends  
Figure 1: Overall survival rate after kidney transplantation for patients with any PTLD (n=13) vs. 
late-onset PTLD (n=10) vs. without PTLD (n=1730). 
Kaplan-Meier curves indicated significantly worse OS rates in patients with PTLD compared 
patients without PTLD (76.9% vs. 97.4% at 5 years, 76.9% vs. 95.4% at 10 years, 65.9% vs. 91.0% 
at 20 years after transplantation, p=0.0001). OS rates was also worse in patients with late-onset 
PTLD than in patients without PTLD, although the difference was not significant (p=0.078). 
 
Figure 2: Graft survival rate after kidney transplantation for patients with overall PTLD (n=13) vs. 
with late-onset PTLD (n=10) vs. without PTLD (n=1730). 
Kaplan-Meier curves indicated that graft survival did not significantly differ between patients with 
and without PTLD (p=0.1612). Furthermore, graft survival did not significantly differ between 
patients with late-onset and patients without PTLD (p=0.7179). 
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Figure 3: Overall survival rate after outbreak of late-onset PTLD 
The 5- and 7- year overall survival rates after late-onset PTLD were 90.0% and 60.0%, respectively.  
 
Figure 4: Graft survival rate after outbreak of late-onset PTLD 
The 1- and 5-year graft survival rates after late-onset PTLD were 80.0% and 40.0%, respectively.  
Table 1: Demographic characteristics of recipients with and without PTLD  between the pre-2000 and post-2000 eras
Without PTLD (pre-2000) With PTLD (pre-2000) Without PTLD (post- 2000) With PTLD (post-2000) Total (pre- 2000) Total (post- 2000) p value
n 540 7 1177 6 547 1183
Age 36.2 (20-66) 44.7 (26-62) 44.3 (20-75) 54 .0 (34-68) 36.3 (20-66) 44.3 (20-75) <0.0001
Sex
male/famale 353/ 187 (65.4%) 7/0 733/ 444 (62.3%) 5/1 360/ 187 (65.8%) 738/ 445 (62.4%) 0.168
ABO compatibility
ABO- compatible
- minor mismatch
- incompatible
386 (71.5%)
87 (16.1%)
67 (12.4%)
4
1
2
675 (57.3%)
198 (16.8%)
304 (25.8%)
4
2
0
390 (71.3%)
88 (16.1%)
69 (12.6%)
679 (57.4%)
200 (16.9%)
304 (25.7%)
<0.0001
Donor source
living donor transplantation
deceased donor transplantation
unknown
482 (89.3%)
49 (9.07%)
9 (1.67%)
4
3
0
1087 (92.4%)
70 (5.95%)
20 (1.70%)
4
2
0
486 (88.8%)
52 (9.51%)
9 (1.65%)
1091 (92.2%)
72 (6.09%)
20 (1.70%)
0.0373
Immunosuppressive drugs at KTx
MP
CYA
FK
AZ
MZ
MMF
EVL
ALG
DSG
BSX
RTX
540 (100.0%)
404 (74.8%)
136 (25.2%)
246 (45.6%)
232 (43.0%)
54 (10.0%)
0 (0.00%)
67 (12.4%)
67 (12.4%)
0 (0.00%)
0 (0.00%)
7
3
4
5
1
1
0
2
2
0
0
1177 (100.0%)
26 (2.21%)
1147 (97.5%)
17 (1.44%)
70 (5.95%)
1087 (92.4%)
1 (0.085%)
0 (0.00%)
0 (0.00%)
896 (76.1%)
550 (46.7%)
6
1
5
0
0
5
1
0
0
4
0
547 (100.0%)
407 (74.4%)
140 (25.6%)
251 (45.9%)
233 (42.6%)
55 (10.1%)
0 (0.00%)
69 (12.6%)
69 (12.6%)
0 (0.00%)
0 (0.00%)
1183 (100.0%)
27 (2.28%)
1152 (97.4%)
17 (1.44%)
70 (5.92%)
1092 (92.3%)
2 (0.17%)
0 (0.00%)
0 (0.00%)
900 (76.1%)
550 (46.5%)
-
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.336
<0.0001
<0.0001
<0.0001
<0.0001
Splenectomy at the time of KTx
yes
no 
unknown
67 (12.4%)
469 (86.9%)
4 (0.74%)
2
0
0
85 (7.22%)
1085 (92.2%)
7 (0.59%)
0
6
0
69 (12.6%)
469 (85.7%)
4 (0.73%)
85 (7.19%)
1091 (92.2%)
7 (0.59%)
0.0010
EBV serostatus
positive
negative 
unknown
123 (22.8%)
14 (2.59%)
403 (74.6%)
4
1
2
989 (84.0%)
70 (5.95%)
118 (10.0%)
4
2
0
127 (23.2%)
15 (2.74%)
405 (74.0%)
993 (83.9%)
72 (6.09%)
118 (9.97%) 
<0.0001
Incidence rate of PTLD-onset 
early-onset PTLD
late-onset PTLD
7 (1.28%)
3 (0.55%)
4 (0.73%)
6 (0.51 %)
0 (0.00 %)
6 (0.51 %)
Immunosuppressive drugs at 
diagnosis of PTLD
MP
CYA
FK
AZ
MZ
MMF
7
1
6
2
1
4
6
0
6
0
0
6
Treatments for PTLD
IR
chemotherapy
with RTX
without RTX
radiation
surgery
7
1
0
1
2
1
6
4
3
1
2
2
PTLD, post-transplant lymphoproliferative disorder; KTx, kidney transplantation; MP, methylprednisolone; CYA, cyclosporine; FK, tacrolimus; AZ, azathioprine; MZ, mizoribine; MMF, mycophenolate mofetil; EVL, everolimus; ALG,
antilymphocyte globlin; DSG, deoxyspergualine; BSX, basiliximab; RTX, rituximab; EBV, Epstein-Barr virus; IR, immunosuppression reduction;
Patient
number 
Age/sex KTx
(year)
Immunosuppressive 
drugs at KTx
EBV-
serostatus
Previous anti-
rejection therapy
Duration from KTx
to onset (months)
Histopathology EBV
association
Presentation  Ann Arbor 
staging
Immunosuppressive
drugs at onset
Early-onset 
(n=3)
1 27/M 1989 CYA, AZ, MP, ALG 
DSG
Positive mPSL, OKT3, 
DSG
8 ML Unknown CNS, hilar LN 4B CYA, AZ, MP
2 26/M 1996 FK, AZ, MP, ALG
DSG
Negative mPSL, OKT3, 
DSG
3 DLBCL, diffuse
mixed
Unknown Neck LNs, axillary LN
inguinal LNs
bone marrow 
4B FK, MZ, MP
3 45/M 1997 FK, AZ, MP Positive mPSL, OKT3 1 B-cell lymphoma Yes Graft, axillary LNs
inguinal LNs
4A FK, AZ, MP
Late-onset 
(n=10)
4 53/M 1990 CYA, MZ, MP Unknown 250 Polymorphic B-cell 
lymphoma 
Yes CNS, abdominal LN 4B FK, MMF, MP
5 47/M 1992 FK, AZ, MP Positive 147 DLBCL No Cervical LN 1A FK, MMF, MP
6 62/M 1995 CYA, AZ, MP Unknown 193 PEL, B-cell 
lymphoma 
Unknown Pleura PEL FK, MMF, MP
7 53/M 1998 FK, MMF, MP Positive 177 Mixed cellularity
Hodgkin lymphoma 
Yes Abdominal LNs 2B FK, MMF, MP
8 64/M 2000 FK, MMF, MP Positive 131 DLBCL Yes Lung, abdominal LNs 
retroperitoneal LNs
3A FK, MMF, MP
9 68/M 2001 FK, MMF, MP Positive 68 DLBCL No Orbit, lung, testis
abdominal LNs
4A FK, MMF, MP
10 52/M 2004 FK, MMF, MP, 
BSX
Positive 23 NHL, T-cell,
monomorphic
Yes Lung, skin 4A FK, MMF, MP
11 39/W 2006 FK, MMF, MP, 
BSX
Negative mPSL, DSG 14 DLBCL Yes Abdominal LNs
small intestine 
4A FK, MMF, MP
12 34/M 2009 CYA, EVL, MP, 
BSX
Negative 45 Burkitt B-cell 
lymphoma
Yes Liver, abdominal LNs
bone marrow
4B FK, MMF, MP
13 67/M 2010 FK, MMF, MP, 
BSX
Positive 39 DLBCL Yes CNS 4B FK, MMF, MP
PTLD, post-transplant lymphoproliferative disorder; KTx, kidney transplantation; EBV, Epstein-Barr viral; CGN, chronic glomerulonephritis; IgAN, IgA nephropatchy; PKD, polycystic kidney disease; CYA, cyclosporine; AZ, azathioprine; MP,
methylprednisolone; ALG, antilymphocyte globulin; DSG, deoxyspergualine; MZ, mizoribine; FK, tacrolimus; MMF, mycophenolate mofetil; BSX, basiliximab; EVL, everolimus; OKT3, muromonab-CD3; mPSL, steroid pulse therapy; ; ML,
malignant lymphoma; DLBCL, diffuse large B-cell lymphoma; PEL, primary effusion lymphoma; NHL; non-Hodgkin lymphoma; CNS, central nervous system; LN, lymph node
Table 2: Individual clinical and histopathological characteristics of PTLD between the early- and late-onset PTLD groups





